Jonathan Tart
AstraZeneca (Singapore)(SG)AstraZeneca (Germany)(DE)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Protein Kinase Regulation and GTPase Signaling, Cancer-related Molecular Pathways, Protease and Inhibitor Mechanisms, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation(2012)169 cited
- → Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation(2015)118 cited
- → Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily(2017)85 cited
- → Integrin α5β1 and ADAM-17 Interact in Vitro and Co-localize in Migrating HeLa Cells(2004)80 cited
- → Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage Patterns(2000)53 cited
- → A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation(2023)36 cited
- → Matrix metalloproteinase 17 is necessary for cartilage aggrecan degradation in an inflammatory environment(2011)35 cited
- → Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets(2020)29 cited
- → Rapid Identification of Novel Allosteric PRC2 Inhibitors(2019)9 cited
- → Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5–6-mer) Peptides(2021)8 cited